Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 56.6× GeneDx Holdings Corp's market cap, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and GeneDx Holdings Corp for 19 Days on average.
| SGOV | WGS | |
|---|---|---|
Market Cap | $114.40B | $2.02B |
Volume | 18,879,081 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $167.51 |
52-Week Low | $100.28 | $34.51 |
Typical Hold Time | 50 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV trades at $100.515 with minimal daily movement (+0.05%). The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent dividends of $0.30-0.31 per share were declared for H2-2026. The ETF focuses on short-term Treasury bonds, with institutional activity showing Envestnet reduced its position by 13.2% in Q2 2026.
The outlook remains cautious amid rising Treasury yields and bond market volatility. Higher interest rates could pressure short-term bond ETFs like SGOV, though they offer relative safety. Key risks include Fed policy shifts and inflation trends. Investors should weigh yield advantages against duration risk in the current rate environment.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
